The Midkine pipeline drugs market research report outlays comprehensive information on the Midkine targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Midkine pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, Genito Urinary System, and Gastrointestinal which include the indications Osteosarcoma, Metastatic Breast Cancer, Inflammation, Autoimmune Disorders, Kidney Fibrosis, Acute Renal Failure (ARF) (Acute Kidney Injury), and Liver Fibrosis. It also reviews key players involved in Midkine targeted therapeutics development with respective active and dormant or discontinued products.
The Midkine pipeline targets constitutes close to nine molecules. Out of which, approximately seven molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in and Preclinical stages are and 7 respectively. Similarly, the universities portfolio in Preclinical comprises 2 molecule.
Midkine overview
Midkine (MDK) or neurite growth-promoting factor 2 is a protein encoded by the MDK gene. It binds to anaplastic lymphoma kinase which induces ALK activation and subsequent phosphorylation of the insulin receptor substrate, activation of mitogen-activated protein kinase and PI3-kinase and the induction of cell proliferation. It is involved in neointima formation after arterial injury and early fetal adrenal gland development.
For a complete picture of Midkine’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
